



| Catalog No. | HB996046 |
|---|---|
| Description |
Blinatumomab (HB996046) is a research-grade recombinant antibody targeting CD19. Produced in mammalian cells with native-like glycosylation.
Highlights
|
| Species reactivity | Human |
| Applications | ELISA, Bioactivity: FACS, Functional assay, Research in vivo |
| Host species | Mouse |
| Isotype | (scFv-kappa-heavy)-(scFv-heavy-kappa) |
| Expression system | Mammalian cells |
| Clonality | Monoclonal |
| Target | CD19, Differentiation antigen CD19, T-cell surface antigen Leu-12, B-lymphocyte antigen CD19, B-lymphocyte surface antigen B4, T3E, T-cell surface antigen T3/Leu-4 epsilon chain, CD3e, CD3E, T-cell surface glycoprotein CD3 epsilon chain |
| Endotoxin level | < 10 EU/mg |
| Purity | >95% purity as determined by SDS-PAGE. |
| Purification | Purified by Nickel column. |
| Accession | P15391 & P07766 |
| Form | Liquid |
| Storage buffer | 30 mM Histidine, pH5.8, 10% sucrose, 0.02% Tween80 Please refer to the specific buffer information in the hardcopy of datasheet or the lot-specific COA. |
| Stability and Storage | Use a manual defrost freezer and avoid repeated freeze thaw cycles. Store at 2 to 8°C for frequent use. Store at -20 to -80°C for twelve months from the date of receipt. |
| Alternate Names | Bispecific, CD19, AMG103, BITEMT-103, MEDI-538, MT103, bscCD19xCD3, 853426-35-4 |
| Background | Blinatumomab (Anatumomab) is a bispecific monoclonal antibody with two binding sites, one for CD3E on T cells and one for CD19 on B cells. Blinatumomab can be used in research for acute lymphoblastic leukemia. |
| Note | For research use only. Not suitable for clinical or therapeutic use. |

SDS-PAGE for Anti-Human CD19 & CD3 epsilon Bispecific Reference Antibody (Blinatumomab, RUO)

SEC-HPLC detection for Research Grade Blinatumomab.
Contact us for custom quotes, bulk requests and any other issues.
Mail: support@abinScience.com




+86-27-65523339
Building C, No. 666, Shen Dun Si Lu, Wuhan, 430206, China
中文
English
한국어
日本語
Español
Français
Русский